Personalis Inc Dossier
Qualitative Analysis
Business overview
Personalis, Inc. (NASDAQ: PSNL) is a leading precision oncology genomics company transforming the development of next-generation therapies and cancer diagnostics. Founded in 2011 and headquartered in Fremont, California, the company provides comprehensive molecular data about each patient's cancer and immune response. Its advanced genomic tests, notably the NeXT Personal Dx minimal residual disease (MRD) test and the ImmunoID NeXT platform, are utilized by biopharmaceutical companies for translational research, biomarker discovery, clinical trials, and personalized cancer vaccine development (such as its high-profile partnership with Moderna and Merck). Additionally, Personalis provides clinical testing services to physicians for early cancer recurrence detection and therapy selection, alongside population sequencing services.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A partner-centric commercial strategy focused on scaling clinical adoption of the ultra-sensitive NeXT Personal MRD platform, primarily leveraging Tempus AI's extensive sales channel to target oncologists.
Expected impact: Aims to quadruple clinical test volumes and more than double strategic revenue (clinical testing and biopharma MRD) to a range of $30.0 million to $32.0 million in 2026.
Intentionally migrating the business model away from lower-margin legacy enterprise sequencing projects (such as Natera and population sequencing) toward high-value clinical diagnostics and biopharma MRD partnerships.
Expected impact: Long-term gross margin expansion and sustainable revenue quality improvement as Medicare and private payer coverage decisions are secured.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Tempus serves as the exclusive commercial diagnostic partner for NeXT Personal Dx in breast and lung cancers, and immunotherapy monitoring. In Q1 2026, Tempus generated over 80% of Personalis' clinical test volume.
Terms: Tempus invested approximately $36 million in Personalis in August 2024 by exercising warrants and purchasing additional shares. Tempus also provides up to $12 million in milestone-based funding for clinical evidence development.
Moderna utilizes Personalis' ImmunoID NeXT Platform to sequence genomic information for its personalized cancer vaccine program (mRNA-4157/V940), jointly developed with Merck.
Terms: Provides a baseline biopharma testing revenue stream projected at $2.0 million to $3.0 million per quarter for the remainder of 2026.
Merck's investment aligns with the co-development of the personalized cancer vaccine program with Moderna, validating Personalis' technology platform.
Terms: Merck purchased $50.0 million of Personalis common stock in a private placement in December 2024, acquiring an approximate 16.5% beneficial ownership interest.